Response to pharmacotherapy and hypofrontality assessed by near-infrared spectroscopy in major depression: Comparison between responders and non-responders

Yosuke Kokubo, Bun Yamagata, Haruhisa Ohta, Hiroi Tomioka, Genshin Minegishi, Masaru Mimura

Research output: Contribution to journalArticle

Abstract

Approximately 30% of patients with depression are reported to be treatment-resistant, and a number of bio-psycho-social factors are known to influence responsiveness to pharmacotherapy. In the present study, we investigated whether pre-treatment frontal functions of patients with depression as measured by near-infrared spectroscopy (NIRS) would predict future responsiveness to pharmacotherapy. Thirty-two drug-naive outpatients with major depressive disorder participated in the present study. All the patients were started with antidepressants and their clinical symptoms were evaluated twice with the Hamilton Rating Scale for Depression (HRS-D), on their first visit and 8-12 weeks after the beginning of pharmacotherapy. All patients received multi-channel NIRS on their first visit, and their frontal reactivity was measured by changes in oxy-hemoglobin concentration in the frontal lobes. Comparison of pre-treatment NIRS findings demonstrated that the overall increase of oxy-hemoglobin in responders was lower than that in non-responders, with significant differences in channels in the medial frontal areas. The results suggest that the treatment-responsive patients with depression demonstrated typical hypofrontality as has been reported in previous literature. In contrast, NIRS findings of the treatment-resistant depressive patients were similar to those reported in healthy persons, suggesting that patients with atypically preserved frontal reactivity may respond minimally to antidepressants. Pre-treatment hypofrontality of patients with depression as measured by NIRS may be useful for predicting future responsiveness to pharmacotherapy.

Original languageEnglish
Pages (from-to)182-189
Number of pages8
JournalJournal of the Showa Medical Association
Volume69
Issue number2
Publication statusPublished - 2009 Apr
Externally publishedYes

Fingerprint

Near-Infrared Spectroscopy
Depression
Drug Therapy
Antidepressive Agents
Hemoglobins
Therapeutics
Major Depressive Disorder
Frontal Lobe
Outpatients
Pharmaceutical Preparations

Keywords

  • Frontal lobe
  • Major depressive disorder
  • Near-infrared spectroscopy
  • Pharmacotherapy
  • Treatment-resistance

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Response to pharmacotherapy and hypofrontality assessed by near-infrared spectroscopy in major depression : Comparison between responders and non-responders. / Kokubo, Yosuke; Yamagata, Bun; Ohta, Haruhisa; Tomioka, Hiroi; Minegishi, Genshin; Mimura, Masaru.

In: Journal of the Showa Medical Association, Vol. 69, No. 2, 04.2009, p. 182-189.

Research output: Contribution to journalArticle

@article{e61e744d85a3413c94d42b041650639a,
title = "Response to pharmacotherapy and hypofrontality assessed by near-infrared spectroscopy in major depression: Comparison between responders and non-responders",
abstract = "Approximately 30{\%} of patients with depression are reported to be treatment-resistant, and a number of bio-psycho-social factors are known to influence responsiveness to pharmacotherapy. In the present study, we investigated whether pre-treatment frontal functions of patients with depression as measured by near-infrared spectroscopy (NIRS) would predict future responsiveness to pharmacotherapy. Thirty-two drug-naive outpatients with major depressive disorder participated in the present study. All the patients were started with antidepressants and their clinical symptoms were evaluated twice with the Hamilton Rating Scale for Depression (HRS-D), on their first visit and 8-12 weeks after the beginning of pharmacotherapy. All patients received multi-channel NIRS on their first visit, and their frontal reactivity was measured by changes in oxy-hemoglobin concentration in the frontal lobes. Comparison of pre-treatment NIRS findings demonstrated that the overall increase of oxy-hemoglobin in responders was lower than that in non-responders, with significant differences in channels in the medial frontal areas. The results suggest that the treatment-responsive patients with depression demonstrated typical hypofrontality as has been reported in previous literature. In contrast, NIRS findings of the treatment-resistant depressive patients were similar to those reported in healthy persons, suggesting that patients with atypically preserved frontal reactivity may respond minimally to antidepressants. Pre-treatment hypofrontality of patients with depression as measured by NIRS may be useful for predicting future responsiveness to pharmacotherapy.",
keywords = "Frontal lobe, Major depressive disorder, Near-infrared spectroscopy, Pharmacotherapy, Treatment-resistance",
author = "Yosuke Kokubo and Bun Yamagata and Haruhisa Ohta and Hiroi Tomioka and Genshin Minegishi and Masaru Mimura",
year = "2009",
month = "4",
language = "English",
volume = "69",
pages = "182--189",
journal = "Showa Igakkai zasshi = The Journal of the Showa Medical Association",
issn = "0037-4342",
publisher = "Showa Medical Association",
number = "2",

}

TY - JOUR

T1 - Response to pharmacotherapy and hypofrontality assessed by near-infrared spectroscopy in major depression

T2 - Comparison between responders and non-responders

AU - Kokubo, Yosuke

AU - Yamagata, Bun

AU - Ohta, Haruhisa

AU - Tomioka, Hiroi

AU - Minegishi, Genshin

AU - Mimura, Masaru

PY - 2009/4

Y1 - 2009/4

N2 - Approximately 30% of patients with depression are reported to be treatment-resistant, and a number of bio-psycho-social factors are known to influence responsiveness to pharmacotherapy. In the present study, we investigated whether pre-treatment frontal functions of patients with depression as measured by near-infrared spectroscopy (NIRS) would predict future responsiveness to pharmacotherapy. Thirty-two drug-naive outpatients with major depressive disorder participated in the present study. All the patients were started with antidepressants and their clinical symptoms were evaluated twice with the Hamilton Rating Scale for Depression (HRS-D), on their first visit and 8-12 weeks after the beginning of pharmacotherapy. All patients received multi-channel NIRS on their first visit, and their frontal reactivity was measured by changes in oxy-hemoglobin concentration in the frontal lobes. Comparison of pre-treatment NIRS findings demonstrated that the overall increase of oxy-hemoglobin in responders was lower than that in non-responders, with significant differences in channels in the medial frontal areas. The results suggest that the treatment-responsive patients with depression demonstrated typical hypofrontality as has been reported in previous literature. In contrast, NIRS findings of the treatment-resistant depressive patients were similar to those reported in healthy persons, suggesting that patients with atypically preserved frontal reactivity may respond minimally to antidepressants. Pre-treatment hypofrontality of patients with depression as measured by NIRS may be useful for predicting future responsiveness to pharmacotherapy.

AB - Approximately 30% of patients with depression are reported to be treatment-resistant, and a number of bio-psycho-social factors are known to influence responsiveness to pharmacotherapy. In the present study, we investigated whether pre-treatment frontal functions of patients with depression as measured by near-infrared spectroscopy (NIRS) would predict future responsiveness to pharmacotherapy. Thirty-two drug-naive outpatients with major depressive disorder participated in the present study. All the patients were started with antidepressants and their clinical symptoms were evaluated twice with the Hamilton Rating Scale for Depression (HRS-D), on their first visit and 8-12 weeks after the beginning of pharmacotherapy. All patients received multi-channel NIRS on their first visit, and their frontal reactivity was measured by changes in oxy-hemoglobin concentration in the frontal lobes. Comparison of pre-treatment NIRS findings demonstrated that the overall increase of oxy-hemoglobin in responders was lower than that in non-responders, with significant differences in channels in the medial frontal areas. The results suggest that the treatment-responsive patients with depression demonstrated typical hypofrontality as has been reported in previous literature. In contrast, NIRS findings of the treatment-resistant depressive patients were similar to those reported in healthy persons, suggesting that patients with atypically preserved frontal reactivity may respond minimally to antidepressants. Pre-treatment hypofrontality of patients with depression as measured by NIRS may be useful for predicting future responsiveness to pharmacotherapy.

KW - Frontal lobe

KW - Major depressive disorder

KW - Near-infrared spectroscopy

KW - Pharmacotherapy

KW - Treatment-resistance

UR - http://www.scopus.com/inward/record.url?scp=72049110488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72049110488&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:72049110488

VL - 69

SP - 182

EP - 189

JO - Showa Igakkai zasshi = The Journal of the Showa Medical Association

JF - Showa Igakkai zasshi = The Journal of the Showa Medical Association

SN - 0037-4342

IS - 2

ER -